Assessment of potential predictive factors of dupilumab response in patients with moderate-to-severe atopic dermatitis.

Gemma Melé-NinotLaia Curto-BarredoMontserrat Bonfill-OrtíVicente Expósito-SerranoMonica Munera CamposIgnasi Figueras NartConstanza Riquelme-Mc LoughlinSara Gómez-ArmayonesJorge SpertinoEsther Serra-Baldrich

Published in: The Australasian journal of dermatology (2023)

Dupilumab was an effective treatment in patients with moderate-to-severe AD. Additionally, sex and body mass index were significantly associated with achieving EASI-75 and an improvement of ≥2 points in the IGA scale, respectively, at week 52.

Keyphrases

atopic dermatitis
body mass index
high intensity
early onset
physical activity
drug induced
randomized controlled trial
clinical trial
risk assessment
human health
replacement therapy
clinical evaluation